
Results
15
Companies which are more than 50% undervalued based on analyst price target.
15 companies
Inventiva
Market Cap: €806.9m
A clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally.
IVA
€3.33
7D
3.3%
1Y
20.9%
Valneva
Market Cap: €438.1m
A specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs.
VLA
€2.29
7D
1.3%
1Y
-6.1%
Cellectis
Market Cap: €204.9m
A clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications.
ALCLS
€2.73
7D
5.6%
1Y
100.9%
Innate Pharma
Market Cap: €160.4m
Operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally.
IPH
€1.65
7D
1.9%
1Y
9.3%
Sensorion
Market Cap: €132.8m
A biotechnology company, engages in the development of novel therapies to restore, treat, and prevent hearing loss disorders in France.
ALSEN
€0.25
7D
5.7%
1Y
-29.0%
OSE Immunotherapeutics
Market Cap: €84.2m
A clinical-stage biotechnology company, develops immunotherapies in the areas of immune-oncology and immune-inflammation in France and internationally.
OSE
€3.43
7D
9.9%
1Y
-30.4%
Adocia
Market Cap: €82.8m
A clinical-stage biotechnology company, researches and develops therapeutic solutions for diabetes and obesity.
ADOC
€3.97
7D
-4.1%
1Y
3.8%
ABIONYX Pharma
Market Cap: €72.0m
A biotech company, discovers and develops therapies for the treatment of renal, metabolic, and ophthalmic diseases in France and the United States.
ABNX
€1.93
7D
-5.7%
1Y
61.2%
AB Science
Market Cap: €60.8m
A clinical-stage company, engages in the research, design, development, and marketing of drugs to address pathologies affecting the peripheral and central nervous system, inflammatory diseases, and cancers in France.
AB
€0.76
7D
-14.7%
1Y
-47.1%
MaaT Pharma
Market Cap: €51.6m
A late-stage clinical company, engages in the development of gut microbiome-driven therapies to modulate the immune system and improve cancer survival.
MAAT
€2.70
7D
13.4%
1Y
-43.8%
THX Pharma Société Anonyme
Market Cap: €50.2m
A biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system disorders.
ALTHX
€3.52
7D
6.0%
1Y
181.6%
Nicox
Market Cap: €34.7m
Operates as an ophthalmology company in France and internationally.
ALCOX
€0.39
7D
3.2%
1Y
74.3%
Advicenne
Market Cap: €32.2m
A specialty pharmaceutical company, develops, commercializes, and markets treatments for rare renal diseases in France and internationally.
ALDVI
€1.62
7D
29.8%
1Y
17.5%
GenSight Biologics
Market Cap: €19.5m
A clinical-stage biotechnology company, discovers, develops, and commercializes novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system.
SIGHT
€0.082
7D
1.7%
1Y
-36.7%
Valbiotis
Market Cap: €19.4m
Engages in the research and development of dietary supplements to prevent metabolic and cardiovascular diseases in France and Asia.
ALVAL
€0.81
7D
0.1%
1Y
-3.5%